🟢 Solid Biosciences is trading 6.4% up in pre-market after UBS initiated Buy coverage

Solid Biosciences is trading at $6.30, up +6.42% pre-market amid recent buying following UBS’s initiation of coverage with a Buy rating.

• UBS initiated coverage on October 15 with a $20 price target.
• Subsequent reporting attributed the prior-session jump to investors digesting that coverage; no fresh company announcement for October 20 was identified.
• The biotech sector is sharply lower pre-market, so it does not explain the rise. Pre-market volume was not provided.